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appearance of skin toxicity and in reducing the number of 
dermal toxicity manifestations in BCP subjected to RT. 
Patient satisfaction was highly positive in the majority of 
cases 
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Purpose/Objective: The purpose of the current clinical trial 
was to evaluate efficiency of palliative external beam 
radiotherapy for symptomatic bone metastases from different 
primary tumors and to search for optimum treatment 
schedules. 
Materials and Methods: The randomized study included 427 
patients treated for 616 sites of bone lesions. Breast was the 
primary site in 67% of cases, prostate - in 7%, lung - in 8%, 
renal - in 6%, other tumors, including sarcomas, melanoma, 
colon cancer and unknown primary site - in 12%. The most 
frequent treatment site was the spine - 48%, followed by 
pelvis - 34%, long bones - 14% and other sites - 4%. The main 
indication for irradiation was pain not alleviated by 
sistematic drug therapy (chemotherapy, target therapy, 
bisphosphonates). Radiotherapy protocol included 
hypofractionation regimes of 2, 3 or 4 fractions of 6,5 Gy 
daily, every two days or every five days and standard 
treatment schedule of 23 fractions of 2 Gy daily. 
Results: The average follow-up period was 41 months. 
General pain relief (complete and partial) was observed in 
95,8% - 100% of sites and was independent of primary tumor, 
metastases localization and irradiation schedules. Complete 
response rate (CRR) was higher for bone metastases from 
breast and prostate cancer 67% and 64% correspondingly in 
comparison with lung and renal cancer - 55% and 33% 
respectively (p<0,05). At small number of observations 
metastases from melanoma and sarcomas proved high 
radiosensitivity with CRR 75% and 69% correspondingly. CRR 
for spine and pelvis localization of metastases was similar - 
63,4% and 59,3%, slightly lower for long bones - 48,3% and 
significantly lower for sacrum isolated metastases - 27% 
(p<0,05). CRR significantly increased from 43,6% to 47,9% and 
64,4% for 2, 3 and 4 fractions of 6,5 Gy correspondingly 
(p<0,03). The pain relapse rate in irradiated zone was 8,2% 
and detected no correlation with histology type, metastatic 
site, dose and fractionation schedules. The acute toxicity 
rate (RTOG/EORTC) comprised 24-32% independently of 
irradiation regimes. Late radiation morbidity was observed in 
15,7% for standard treatment schedule and decreased in 
consecutive way for 4, 3 and 2 fractions of 6,5 Gy (14,4%, 
10,9% and 8,3% respectively). Late toxicity grade 2 was 
significantly lower (1,7%, p<0,05) for 3 fractions regime. 
Conclusions: Histogenesis of primary tumor is a predictor of 
radiosensitivity of bone metastases, it significantly affects 
the complete pain response rate. It is expedient to use 
hypofractionation regimes of 3 fractions of 6,5 Gy (total dose 
19,5 Gy) for palliative radiotherapy for bone metastases in 
case of breast and prostate cancer and 4 fractions of 6,5 Gy 
(total dose 26 Gy) in case of lung and renal cancer daily, 
every two days or every five days. In the multifactorial 
analysis tumor primary site and pain intensity before 
radiotherapy were the only independent prognostic factors of 
CRR.  
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Purpose/Objective: The assessment of response to 
radioembolization (RE) of liver metastases is difficult because 
the effect of the radiation on tumour burden is quite 
different from those of chemotherapeutic agents, and 
patients undergo this treatment after multiple systemic and 
regional therapies which determine dramatic changes in liver 
density - caused by necrosis or sclerosis. 18F-FDG-PET/CT has 
been documented as a powerful tool in this respect, 
nonetheless there is not agreement about the optimal 
imaging choice (CT vs. FDG-PET/CT). We investigated the 
accuracy of different parameters derived from CT and 18F-
FDG PET/CT in early predicting the outcome after RE 
Materials and Methods: Patients with chemo-refractory liver 
metastases from solid tumours scheduled to receive RE 
underwent 18F-FDG-PET/CT and CT scan before and 6 weeks 
after RE. Response to treatment was assessed in PET 
according to PERCIST criteria, and metabolic tumour volume 
(MTV), in CT according to RECIST criteria. Overall survival 
(OS) rates were calculated using the Kaplan Meyer method, 
and differences among scoring criteria were explored with 
the log-rank test 
Results: 22 patients were suitable for analysis. All patients 
received a single treatment of RE, with a median activity of 
1.7 GBq (range 0.6-2.9) of 90Y microspheres. Metabolic 
response correlated significantly with OS. For PERCIST, the 
median OS was 28.4 months (95 % CI, 12.4–44.4 mo) in 
patients with CR, 17.7 mo (5.0–30.5 mo) in patients with PR 
and 4.8 mo (2.9–6.8 mo) in those who had SD (see Figure 1). 
All these differences were statistically significant (p<0.05). 
Moreover, responders (CR+PR) had a median OS of 20.6 mo 
(5.7–35.5 mo) with a significant longer OS compared to those 
who showed SD. 
MTV did not produce the expected results, i.e. did not 
correlate with the survival. In several patients we 
experienced some difficulty in defining lesion margins and 
establishing a threshold vs the surrounding liver parenchyma. 
Concerning RECIST criteria, there was no straight separation 
between patients who responded to RE and those who did 
not. The median OS for patients with PR, SD and PD was 20.6 
(14.5-32.8 months), 11.8 (7.9-29.6 months), and 2.7 months 
(0-15.5 months), respectively. Despite the median response 
values were separated, the statistical analysis of the survival 
curves did not reveal any significant difference among the 
four scores (CR, PR, SD, PD).  
